Some notable properties of the standard oncology phase i design

Journal of Biopharmaceutical Statistics

Volumn 19, Issue 3, 2009, Pages 543-555

  Hather, Gregory J ^a   MacKey, Howard ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENENTECH INC   (United States)

Author keywords

3+3; Oncology; Phase I; Standard design

Indexed keywords

ARTICLE; BAYES THEOREM; CALCULATION; DRUG SAFETY; MAXIMUM TOLERATED DOSE; METHODOLOGY; ONCOLOGY; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STANDARD; HUMAN; REGRESSION ANALYSIS; STATISTICS;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; MAXIMUM TOLERATED DOSE; MEDICAL ONCOLOGY; REGRESSION ANALYSIS; RESEARCH DESIGN;

EID: 67651061450     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400902802466     Document Type: Article

References (21)

1. Arbuck, S. G. (1996). Workshop on Phase I study design: Ninth NCI/EORTC new drug development symposium, Amsterdam, March 12, 1996. Ann. Oncol. 7:567-573.
2. Babb, J., Rogatko, A., Zacks, S. (1998). Cancer Phase I clinical trials: Efficient dose escalation with overdose control. Stat. Med. 17:1103-1120. (Pubitemid 28221028)
3. Durham, S. D., Flournoy, N. (1994). Random walks for quantile estimation. In: Gupta, S. S., Berger, J. O., eds. Statistical Decision Theory and Related Topics V. New York: Springer, pp. 467-476.
4. Ivanova, A., Flournoy, N., Chung, Y. (2007). Cumulative cohort design for dose-finding. J. Stat. Plan. Infer. 137:2316-2327.
5. Ivanova, A., Montazer-Haghighi, A., Mohanty, S. G., Durham, S. D. (2003). Improved up-and-down designs for Phase I trials. Stat. Med. 22:69-82.
6. Ji, Y., Li, Y., Bekele, N. (2007). Dose-finding in Phase I clinical trials based on toxicity probability intervals. Clin. Trials 4:235-244.
7. Koyfman, S. A., Agrawal, M., Garrett-Mayer, E., Krohmal, B., Wolf, E., Emanuel, E. J., Gross, C. P. (2007). Risks and benefits associated with novel Phase 1 oncology trial designs. Cancer 110:1115-1124.
8. Leung, D. H. Y., Wang, Y. G. (2001). Isotonic designs for Phase I trials. Controlled Clin. Trials 22:126-138.
9. Lin, Y., Shih, W. J. (2001). Statistical properties of the traditional algorithm-based designs for Phase I cancer clinical trials. Biostatistics 2:203-215.
10. Omura, G. A. (2003). Modified Fibonacci search. J. Clin. Oncol. 21:3177.
11. O'Quigley, J., Pepe, M., Fisher, L. (1990). Continual reassessment method: a practical design for Phase I clinical trials in cancer. Biometrics 46:33-48.
12. Potter, D. M. (2006). Phase I studies of chemotherapeutic agents in cancer patients: A review of the designs. J. Biopharm. Stat. 16:579-604.
13. Reiner, E., Paoletti, X., O'Quigley, J. (1999). Operating characteristics of the standard Phase I clinical trial design. Comput. Stat. Data Anal. 30:303-315.
14. Robertson, T., Wright, F. T., Dykstra, R. L. (1988). Order Restricted Statistical Inference. Chichester: Wiley.
15. Rosenberger, W. F., Haines, L. M. (2002). Competing designs for Phase I clinical trials: a review. Stat. Med. 21:2757-2770.
16. Smith, T. L., Lee, J. J., Kantarjian, H. M., Legha, S. S., Raber, M. N. (1996). Design and results of Phase I cancer clinical trials: Three-year experience at MD Anderson Cancer Center. J. Clin. Oncol. 14:287-295.
17. Simon, R. (1997). Accelerated titration designs for Phase I clinical trials in oncology. J. Natl. Cancer. Inst. 89:1138-1147.
18. Storer, B. (1989). Design and analysis of Phase I clinical trials. Biometrics 45:925-937.
19. Storer, B. (2001). An evaluation of Phase I clinical trial designs in the continuous doseresponse setting. Stat. Med. 20:2399-2408.
20. Stylianou, M., Flournoy, N. (2002). Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics 58:171-177.
21. Sun, J. (1998). Interval censoring. Encyclopedia of Biostatistics. New York: John Wiley & Sons Ltd., pp. 2090-2095.